Myelomatous meningitis

Marc C. Chamberlain, Michael Glantz

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

BACKGROUND. The most frequent nervous system complications of multiple myeloma are peripheral neuropathy and epidural spinal cord compression. Myelomatous meningitis (MM) has been considered rare. The current study was performed to characterize the clinical presentation, treatment, and outcome of MM. METHODS. The study was a case series of 14 patients with cerebrospinal fluid (CSF)-positive MM who were treated at a tertiary care university medical center. RESULTS. Fourteen patients with advanced multiple myeloma were treated with involved-field radiotherapy (to the brain in 5 patients and the spine in 6 patients) and intra-CSF chemotherapy (ventricular in 10 patients and lumbar in 4 patients). The best response to treatment included 6 partial responses and 8 patients with progressive disease. The median duration of response was 2.5 months (range, 0-6 months). Cause of death was progressive neurologic disease in 6 patients, combined systemic and neurologic disease in 6 patients, and systemic disease progression in 2 patients. CONCLUSIONS. MM is rare and morbid entity (6-month neurologic disease progression-free survival rate of 7%), and appears to be no more responsive to treatment than solid tumor carcinomatous meningitis.

Original languageEnglish (US)
Pages (from-to)1562-1567
Number of pages6
JournalCancer
Volume112
Issue number7
DOIs
StatePublished - Apr 1 2008

Fingerprint

Meningitis
Nervous System Diseases
Multiple Myeloma
Disease-Free Survival
Cerebrospinal Fluid
Disease Progression
Meningeal Carcinomatosis
Spinal Cord Compression
Peripheral Nervous System Diseases
Tertiary Healthcare
Nervous System
Cause of Death
Spine
Radiotherapy
Survival Rate
Drug Therapy
Brain
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Chamberlain, Marc C. ; Glantz, Michael. / Myelomatous meningitis. In: Cancer. 2008 ; Vol. 112, No. 7. pp. 1562-1567.
@article{113ec35869164aea94887674e0ef2753,
title = "Myelomatous meningitis",
abstract = "BACKGROUND. The most frequent nervous system complications of multiple myeloma are peripheral neuropathy and epidural spinal cord compression. Myelomatous meningitis (MM) has been considered rare. The current study was performed to characterize the clinical presentation, treatment, and outcome of MM. METHODS. The study was a case series of 14 patients with cerebrospinal fluid (CSF)-positive MM who were treated at a tertiary care university medical center. RESULTS. Fourteen patients with advanced multiple myeloma were treated with involved-field radiotherapy (to the brain in 5 patients and the spine in 6 patients) and intra-CSF chemotherapy (ventricular in 10 patients and lumbar in 4 patients). The best response to treatment included 6 partial responses and 8 patients with progressive disease. The median duration of response was 2.5 months (range, 0-6 months). Cause of death was progressive neurologic disease in 6 patients, combined systemic and neurologic disease in 6 patients, and systemic disease progression in 2 patients. CONCLUSIONS. MM is rare and morbid entity (6-month neurologic disease progression-free survival rate of 7{\%}), and appears to be no more responsive to treatment than solid tumor carcinomatous meningitis.",
author = "Chamberlain, {Marc C.} and Michael Glantz",
year = "2008",
month = "4",
day = "1",
doi = "10.1002/cncr.23330",
language = "English (US)",
volume = "112",
pages = "1562--1567",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

Chamberlain, MC & Glantz, M 2008, 'Myelomatous meningitis', Cancer, vol. 112, no. 7, pp. 1562-1567. https://doi.org/10.1002/cncr.23330

Myelomatous meningitis. / Chamberlain, Marc C.; Glantz, Michael.

In: Cancer, Vol. 112, No. 7, 01.04.2008, p. 1562-1567.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Myelomatous meningitis

AU - Chamberlain, Marc C.

AU - Glantz, Michael

PY - 2008/4/1

Y1 - 2008/4/1

N2 - BACKGROUND. The most frequent nervous system complications of multiple myeloma are peripheral neuropathy and epidural spinal cord compression. Myelomatous meningitis (MM) has been considered rare. The current study was performed to characterize the clinical presentation, treatment, and outcome of MM. METHODS. The study was a case series of 14 patients with cerebrospinal fluid (CSF)-positive MM who were treated at a tertiary care university medical center. RESULTS. Fourteen patients with advanced multiple myeloma were treated with involved-field radiotherapy (to the brain in 5 patients and the spine in 6 patients) and intra-CSF chemotherapy (ventricular in 10 patients and lumbar in 4 patients). The best response to treatment included 6 partial responses and 8 patients with progressive disease. The median duration of response was 2.5 months (range, 0-6 months). Cause of death was progressive neurologic disease in 6 patients, combined systemic and neurologic disease in 6 patients, and systemic disease progression in 2 patients. CONCLUSIONS. MM is rare and morbid entity (6-month neurologic disease progression-free survival rate of 7%), and appears to be no more responsive to treatment than solid tumor carcinomatous meningitis.

AB - BACKGROUND. The most frequent nervous system complications of multiple myeloma are peripheral neuropathy and epidural spinal cord compression. Myelomatous meningitis (MM) has been considered rare. The current study was performed to characterize the clinical presentation, treatment, and outcome of MM. METHODS. The study was a case series of 14 patients with cerebrospinal fluid (CSF)-positive MM who were treated at a tertiary care university medical center. RESULTS. Fourteen patients with advanced multiple myeloma were treated with involved-field radiotherapy (to the brain in 5 patients and the spine in 6 patients) and intra-CSF chemotherapy (ventricular in 10 patients and lumbar in 4 patients). The best response to treatment included 6 partial responses and 8 patients with progressive disease. The median duration of response was 2.5 months (range, 0-6 months). Cause of death was progressive neurologic disease in 6 patients, combined systemic and neurologic disease in 6 patients, and systemic disease progression in 2 patients. CONCLUSIONS. MM is rare and morbid entity (6-month neurologic disease progression-free survival rate of 7%), and appears to be no more responsive to treatment than solid tumor carcinomatous meningitis.

UR - http://www.scopus.com/inward/record.url?scp=41149164311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149164311&partnerID=8YFLogxK

U2 - 10.1002/cncr.23330

DO - 10.1002/cncr.23330

M3 - Article

C2 - 18260094

AN - SCOPUS:41149164311

VL - 112

SP - 1562

EP - 1567

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -

Chamberlain MC, Glantz M. Myelomatous meningitis. Cancer. 2008 Apr 1;112(7):1562-1567. https://doi.org/10.1002/cncr.23330